A piece of news
Biocat CEO Montserrat Vendrell is also in the United States to attend this forum, as well as the JP Morgan Healthcare Conference.
A delegation of nine Spanish biotechnology companies —five of which are Catalan— is participating in the Biotech Showcase investment forum from 9 through 11 January 2011 in San Francisco (United States). Biocat CEO Dr. Montserrat Vendrell is also on a scouting mission to San Francisco, during which she will visit this forum and has been invited to participate in the JP Morgan Healthcare Conference.
The Biotech Showcase is one of the top investment forums in the life sciences sector. It is organized by the EBD Group, which also leads other top-notch partnering congresses like BIO-Europe and BIO-Europe Spring. This year, participants include some 200 companies, 1,300 delegates and leading investment firms like Abingworth Management, Aescap Venture, Atlas Ventures, Bay City Capital, Index Ventures, Goldman Sachs, LifeTech Capital, Life Science Angels, Sikich Investment Banking, Pappas Ventures, Sofinnova Ventures and Yorkville Advisors.
Carola Schropp, president of the EBD Group: “This is the home base for the innovator class of life science companies, and the firms that aim to invest.”
"Each year during the second week of January, San Francisco becomes the Mecca for life science companies and investors," explained Carola Schropp, president of the EBD Group. "This is the home base for the innovator class of life science companies, and the firms that aim to invest in or partner with them," added Schropp.
The San Francisco area is home to the most important life sciences investment community in the world. Specifically, 33% of all biotech venture capital investment in the United States takes place in this region.
Over these three days, Spanish biotech companies have a full agenda of one-to-one meetings with possible partners and six of them have been selected to present their company to investors:
All of these companies that participate in the delegation have received grants from the ICEX —as part of their internationalization plan for the biotech sector— and Genoma España.
Related news (28/10/2011)